People · Operator
Named in public records as an officer, director or promoter · active 2009–2022 · Biotechnology, Other Health Care, Other Technology, Other Energy
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cardiodx Inc | — | Biotechnology | Series C | $174.0M | $742.4M | 2010 |
| iRhythm Technologies, Inc. | — | Other Health Care | Series B | $118.6M | $605.8M | 2009 |
| SURGE Therapeutics, Inc. | — | Biotechnology | Series B | $52.6M | $368.8M | 2020 |
| XDx, Inc. | — | Biotechnology | Series B | $44.5M | $879.9M | 2016 |
| Yor Labs, Inc. | — | Biotechnology | Series B | $37.7M | $167.0M | 2019 |
| Dnanexus, Inc. | — | Biotechnology | Series A | $31.6M | $542.3M | 2013 |
| Corventis Inc | — | Biotechnology | Series A | $10.0M | $361.5M | 2009 |
| Counslr, Inc. | — | Other Technology | Series A | $5.2M | $68.5M | 2022 |
| Meditope Biosciences, Inc. | — | Biotechnology | Seed | $3.7M | $72.1M | 2015 |
| Civicsolar, Inc | — | Other Energy | Seed | $3.6M | $41.5M | 2010 |
| Cognotion, Inc. | — | Other Technology | Seed | $3.0M | $8.5M | 2014 |
Michael Goldberg at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Goldberg on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Brook Byers | 2 | 13 |
| William Starling | 2 | 4 |
| David Levison | 2 | 3 |
| Michael D. Goldberg | 2 | 3 |
| William Willis | 2 | 3 |
| William F. Willis | 2 | 2 |
| Fred Cohen | 1 | 12 |
| Patrick Enright | 1 | 10 |
| Risa Stack | 1 | 9 |
| ROB HAYES | 1 | 9 |
| Vijay Lathi | 1 | 8 |
| Dana G. Mead, Jr. | 1 | 7 |
| G. Steven Burrill | 1 | 7 |
| Patrick G. Enright | 1 | 7 |
| William Ericson | 1 | 6 |
| James R. Tobin | 1 | 6 |
| Gary Goldberg | 1 | 5 |
| Ajit Singh | 1 | 5 |
| William N. Starling | 1 | 5 |
| Krishna Yeshwant | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.